Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma

Md. Zillur Rahman Bhuiyan; Rokaya Sultana; Ranjan Kumar Bhoumic; Sayed Farhan Ali Razib; Ashish Kumar Shaha; Ariful Haque

doi:doi:10.11648/j.crj.20210903.16

Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma

Md. Zillur Rahman Bhuiyan, Rokaya Sultana, Ranjan Kumar Bhoumic, Sayed Farhan Ali Razib, Ashish Kumar Shaha, Ariful Haque

Published in Cancer Research Journal (Volume 9, Issue 3)

Received: 3 August 2021 Accepted: 12 August 2021 Published: 24 August 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Head neck carcinoma is the sixth most common cancer in the world. Concurrent chemo radiation became standard protocol for patients with locally advanced squamous cell carcinoma of head neck where curable surgery is not feasible. Study Design and Objective: This quasiexperimental study done to compare the treatment response and acute toxicities with the treatment of low dose weekly Paclitaxel with radiation versus weekly Cisplatin with radiation therapy for histologically proven Stage- IVA squamous cell carcinoma of head neck. Methods: All the patients were divided in two groups. Arm-A, 45 number patients received injection Paclitaxel 40 mg/m², i/v in 1 hr. infusion weekly for 6 weeks and in Arm- B, 45 number patients received injection Cisplatin 30 mg/m², i/v in 2 hrs infusion weekly for 6 weeks. All patients received 66 Gray (Gy) radiation at the rate of 2 Gy/day, 5 fractions in a week for 6.5 weeks. Results: In this study about 65.55% patients were smoker. Most common sub site was larynx (41.46%) followed by oral cavity (25.00%) The most common presenting features were cervical lymphadenopathy (100.00%) followed by pain (70.00%), sore throat (43.33%) and hoarseness of voice (41.11%). Complete response showed in the patients of Arm-A, 73.33% among the smoker and 66.67% in non-smoker, whereas 72.41% in smoker and 62.50% in non-smoker showed complete response in the patients of Arm-B. Common toxicities related to treatment were mucosities, skin reaction, vomiting, nausea, weight loss, anaemia, leucopcnia, thrombocytopenia and diarrhoea. The toxicities in Arm-A were more than that of Arm-B, but were manageable. Conclusion: In this study it is evident, the concurrent chemo radiotherapy with weekly Paclitaxel is suitable alternative when Cisplatin cannot be given safely.

Published in	Cancer Research Journal (Volume 9, Issue 3)
DOI	10.11648/j.crj.20210903.16
Page(s)	166-170
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Paclitaxel, Cisplatin: (Anti Cancer Drugs), Gy (Gray): Radiation Unit, CCRT: (Concurrent Chemoradiotherapy:), Locally Advanced Head Neck Carcinoma

References

[1]	AJCC Cancer Staging Manual. 7^lh edition. New York, NY: Spingcr- Vcrlag, 2010.
[2]	Bomford CK, Kunkler IH, Sherrif SB. Miller Text Book of Radiotherapy, Radiation Physics, Therapy and Oncology, 6, h edition, Edinburgh Churchill Livingstone, 2003; pp 355-70.
[3]	Cancer Registry Report 2008-2010, Distribution of patients by systemic diagnosis. Cancer Registry Report, National Institute of Cancer Research and Hospital, Mohakhali. Dhaka, pp 10-18.
[4]	Chu E, DeVitaJr VT. Physicians' Cancer Chemotherapy Drug Manual 2013, 13th edition, Jones & Bartlett learning. LLC. an Ascend Learning Company, 2013; pp 303-307.
[5]	DevitaJr VT. Lawrence TS, Rosenberg SA. Cancer Principles & Practice of Oncology, 10^th edition, Lippincot Williams & Wilkins. 2015; pp 424-464.
[6]	Dobbs J, Banett A. Ash D. Practical radiotherapy Planning. 4^thedition, UK, 2009; 88-94.
[7]	GLOBOCAN database. 2012., International agency for research on cancer, WHO. Cancer Incidence and Mortality
[8]	Halperin EC, Perez CA, Brady LW. Perez and Brady's Principles and Practice of Oncology, 6^th edition, Lippincot Williams & Wilkins, 2013; 718-729.
[9]	Pazdur R, Wagman LD, Camhausen KA, Hoskins WJ. Cancer Management: A Multidisciplinary' Approach, 13th edition, UBM Medica LLC, New York, 2010.
[10]	Perri F, Integrated therapeutic approaches in head neck cancer: the importance of multidisciplinary team management Anticancer Agents Med. Chem. 2013; 13: 834-43.
[11]	RTOG 0417, this protocol was designed and developed by the Radiation Therapy Oncology Group (RTOG) of the American College of Radiology (ACR).
[12]	Symonds P, Deehan C, Mills JA, Meredith C. Walter and Miller's Textbook of Radiotherapy, 7th edition. Churchil Livingstone, London. 2012; pp 341-380.
[13]	WHO. 2002. National Cancer Control Programmes: Policies and managerial guidelines. 2nd ed. Geneva: World Health Organization.

Cite This Article

Plain Text BibTeX RIS

APA Style

Md. Zillur Rahman Bhuiyan, Rokaya Sultana, Ranjan Kumar Bhoumic, Sayed Farhan Ali Razib, Ashish Kumar Shaha, et al. (2021). Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma. Cancer Research Journal, 9(3), 166-170. https://doi.org/10.11648/j.crj.20210903.16

Copy | Download

ACS Style

Md. Zillur Rahman Bhuiyan; Rokaya Sultana; Ranjan Kumar Bhoumic; Sayed Farhan Ali Razib; Ashish Kumar Shaha, et al. Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma. Cancer Res. J. 2021, 9(3), 166-170. doi: 10.11648/j.crj.20210903.16

Copy | Download

AMA Style

Md. Zillur Rahman Bhuiyan, Rokaya Sultana, Ranjan Kumar Bhoumic, Sayed Farhan Ali Razib, Ashish Kumar Shaha, et al. Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma. Cancer Res J. 2021;9(3):166-170. doi: 10.11648/j.crj.20210903.16

Copy | Download

@article{10.11648/j.crj.20210903.16,
  author = {Md. Zillur Rahman Bhuiyan and Rokaya Sultana and Ranjan Kumar Bhoumic and Sayed Farhan Ali Razib and Ashish Kumar Shaha and Ariful Haque},
  title = {Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma},
  journal = {Cancer Research Journal},
  volume = {9},
  number = {3},
  pages = {166-170},
  doi = {10.11648/j.crj.20210903.16},
  url = {https://doi.org/10.11648/j.crj.20210903.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20210903.16},
  abstract = {Introduction: Head neck carcinoma is the sixth most common cancer in the world. Concurrent chemo radiation became standard protocol for patients with locally advanced squamous cell carcinoma of head neck where curable surgery is not feasible. Study Design and Objective: This quasiexperimental study done to compare the treatment response and acute toxicities with the treatment of low dose weekly Paclitaxel with radiation versus weekly Cisplatin with radiation therapy for histologically proven Stage- IVA squamous cell carcinoma of head neck. Methods: All the patients were divided in two groups. Arm-A, 45 number patients received injection Paclitaxel 40 mg/m2, i/v in 1 hr. infusion weekly for 6 weeks and in Arm- B, 45 number patients received injection Cisplatin 30 mg/m2, i/v in 2 hrs infusion weekly for 6 weeks. All patients received 66 Gray (Gy) radiation at the rate of 2 Gy/day, 5 fractions in a week for 6.5 weeks. Results: In this study about 65.55% patients were smoker. Most common sub site was larynx (41.46%) followed by oral cavity (25.00%) The most common presenting features were cervical lymphadenopathy (100.00%) followed by pain (70.00%), sore throat (43.33%) and hoarseness of voice (41.11%). Complete response showed in the patients of Arm-A, 73.33% among the smoker and 66.67% in non-smoker, whereas 72.41% in smoker and 62.50% in non-smoker showed complete response in the patients of Arm-B. Common toxicities related to treatment were mucosities, skin reaction, vomiting, nausea, weight loss, anaemia, leucopcnia, thrombocytopenia and diarrhoea. The toxicities in Arm-A were more than that of Arm-B, but were manageable. Conclusion: In this study it is evident, the concurrent chemo radiotherapy with weekly Paclitaxel is suitable alternative when Cisplatin cannot be given safely.},
 year = {2021}
}

Copy | Download

TY - JOUR
T1 - Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma
AU - Md. Zillur Rahman Bhuiyan
AU - Rokaya Sultana
AU - Ranjan Kumar Bhoumic
AU - Sayed Farhan Ali Razib
AU - Ashish Kumar Shaha
AU - Ariful Haque
Y1 - 2021/08/24
PY - 2021
N1 - https://doi.org/10.11648/j.crj.20210903.16
DO - 10.11648/j.crj.20210903.16
T2 - Cancer Research Journal
JF - Cancer Research Journal
JO - Cancer Research Journal
SP - 166
EP - 170
PB - Science Publishing Group
SN - 2330-8214
UR - https://doi.org/10.11648/j.crj.20210903.16
AB - Introduction: Head neck carcinoma is the sixth most common cancer in the world. Concurrent chemo radiation became standard protocol for patients with locally advanced squamous cell carcinoma of head neck where curable surgery is not feasible. Study Design and Objective: This quasiexperimental study done to compare the treatment response and acute toxicities with the treatment of low dose weekly Paclitaxel with radiation versus weekly Cisplatin with radiation therapy for histologically proven Stage- IVA squamous cell carcinoma of head neck. Methods: All the patients were divided in two groups. Arm-A, 45 number patients received injection Paclitaxel 40 mg/m2, i/v in 1 hr. infusion weekly for 6 weeks and in Arm- B, 45 number patients received injection Cisplatin 30 mg/m2, i/v in 2 hrs infusion weekly for 6 weeks. All patients received 66 Gray (Gy) radiation at the rate of 2 Gy/day, 5 fractions in a week for 6.5 weeks. Results: In this study about 65.55% patients were smoker. Most common sub site was larynx (41.46%) followed by oral cavity (25.00%) The most common presenting features were cervical lymphadenopathy (100.00%) followed by pain (70.00%), sore throat (43.33%) and hoarseness of voice (41.11%). Complete response showed in the patients of Arm-A, 73.33% among the smoker and 66.67% in non-smoker, whereas 72.41% in smoker and 62.50% in non-smoker showed complete response in the patients of Arm-B. Common toxicities related to treatment were mucosities, skin reaction, vomiting, nausea, weight loss, anaemia, leucopcnia, thrombocytopenia and diarrhoea. The toxicities in Arm-A were more than that of Arm-B, but were manageable. Conclusion: In this study it is evident, the concurrent chemo radiotherapy with weekly Paclitaxel is suitable alternative when Cisplatin cannot be given safely.
VL - 9
IS - 3
ER -

Copy | Download

Author Information

Md. Zillur Rahman Bhuiyan

Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Rokaya Sultana

Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Ranjan Kumar Bhoumic

Department of Radiotherapy, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Sayed Farhan Ali Razib

Department of Head Neck Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Ashish Kumar Shaha

Department of Radiotherapy, Dhaka Medical College Hospital, Dhaka, Bangladesh
Ariful Haque

Department of Radiotherapy, Dhaka Medical College Hospital, Dhaka, Bangladesh

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Md. Zillur Rahman Bhuiyan, Rokaya Sultana, Ranjan Kumar Bhoumic, Sayed Farhan Ali Razib, Ashish Kumar Shaha, et al. (2021). Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma. Cancer Research Journal, 9(3), 166-170. https://doi.org/10.11648/j.crj.20210903.16

Copy | Download

ACS Style

Md. Zillur Rahman Bhuiyan; Rokaya Sultana; Ranjan Kumar Bhoumic; Sayed Farhan Ali Razib; Ashish Kumar Shaha, et al. Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma. Cancer Res. J. 2021, 9(3), 166-170. doi: 10.11648/j.crj.20210903.16

Copy | Download

AMA Style

Md. Zillur Rahman Bhuiyan, Rokaya Sultana, Ranjan Kumar Bhoumic, Sayed Farhan Ali Razib, Ashish Kumar Shaha, et al. Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma. Cancer Res J. 2021;9(3):166-170. doi: 10.11648/j.crj.20210903.16

Copy | Download

@article{10.11648/j.crj.20210903.16,
  author = {Md. Zillur Rahman Bhuiyan and Rokaya Sultana and Ranjan Kumar Bhoumic and Sayed Farhan Ali Razib and Ashish Kumar Shaha and Ariful Haque},
  title = {Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma},
  journal = {Cancer Research Journal},
  volume = {9},
  number = {3},
  pages = {166-170},
  doi = {10.11648/j.crj.20210903.16},
  url = {https://doi.org/10.11648/j.crj.20210903.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20210903.16},
  abstract = {Introduction: Head neck carcinoma is the sixth most common cancer in the world. Concurrent chemo radiation became standard protocol for patients with locally advanced squamous cell carcinoma of head neck where curable surgery is not feasible. Study Design and Objective: This quasiexperimental study done to compare the treatment response and acute toxicities with the treatment of low dose weekly Paclitaxel with radiation versus weekly Cisplatin with radiation therapy for histologically proven Stage- IVA squamous cell carcinoma of head neck. Methods: All the patients were divided in two groups. Arm-A, 45 number patients received injection Paclitaxel 40 mg/m2, i/v in 1 hr. infusion weekly for 6 weeks and in Arm- B, 45 number patients received injection Cisplatin 30 mg/m2, i/v in 2 hrs infusion weekly for 6 weeks. All patients received 66 Gray (Gy) radiation at the rate of 2 Gy/day, 5 fractions in a week for 6.5 weeks. Results: In this study about 65.55% patients were smoker. Most common sub site was larynx (41.46%) followed by oral cavity (25.00%) The most common presenting features were cervical lymphadenopathy (100.00%) followed by pain (70.00%), sore throat (43.33%) and hoarseness of voice (41.11%). Complete response showed in the patients of Arm-A, 73.33% among the smoker and 66.67% in non-smoker, whereas 72.41% in smoker and 62.50% in non-smoker showed complete response in the patients of Arm-B. Common toxicities related to treatment were mucosities, skin reaction, vomiting, nausea, weight loss, anaemia, leucopcnia, thrombocytopenia and diarrhoea. The toxicities in Arm-A were more than that of Arm-B, but were manageable. Conclusion: In this study it is evident, the concurrent chemo radiotherapy with weekly Paclitaxel is suitable alternative when Cisplatin cannot be given safely.},
 year = {2021}
}

Copy | Download